Nov 6 (Reuters) - Novo Nordisk said it
currently expects an estimated negative low single-digit impact
to global sales growth in 2026 after the drugmaker unveiled a
deal on Thursday to slash prices of popular GLP-1 weight-loss
drugs for U.S. government-backed insurance programs and cash
payers.